BIONET TX Corp (7808.TWO)
- Previous Close
44.10 - Open
43.20 - Bid 42.30 x --
- Ask 43.70 x --
- Day's Range
43.00 - 43.50 - 52 Week Range
37.70 - 72.60 - Volume
7,000 - Avg. Volume
47,121 - Market Cap (intraday)
3.045B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.50 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BIONET Therapeutics Corp., a biopharmaceutical company, develops cell therapy products and drug development for acute and severe diseases. The company develops treatment for adult respiratory distress syndrome, pulmonary fibrosis, chronic kidney failure, acute wound healing, chronic wound healing of diabetic ulcers, osteoarthritis, and dry eye syndrome. It also provides CRDMO services. The company was founded in 2022 and is based in Taipei, Taiwan.
www.bionettx.comRecent News: 7808.TWO
View MorePerformance Overview: 7808.TWO
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 7808.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 7808.TWO
View MoreValuation Measures
Market Cap
3.04B
Enterprise Value
1.83B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
30.72
Price/Book (mrq)
2.35
Enterprise Value/Revenue
22.51
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-106.07%
Return on Assets (ttm)
-6.57%
Return on Equity (ttm)
-9.46%
Revenue (ttm)
81.32M
Net Income Avi to Common (ttm)
-86.26M
Diluted EPS (ttm)
-1.50
Balance Sheet and Cash Flow
Total Cash (mrq)
1.21B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-116.82M